Notably, chemotherapy (Ara-C, other than high dose-Ara-C), consolidation therapy (high dose Ara-C), FLT3 inhibitors (FLT3i), and IDH inhibitors (IDH1/IDH2) were selected to be included in the inferred model for every run, emphasizing their critical importance for AML management. This evidence concerns the gene IDH2 and acute myeloid leukemia.